TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN SUMMARY, CHILD HEALTH DISPARITIES SUBSTUDY

Data collection activity		Type of respondent	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours
Consent	Pregnant Women/ Mothers of children ages 0–5.	Members of NCS target population (not NCS participants).	1,260	1	0.08	105
Cognitive Interview	Mothers of children ages 0–5.	Members of NCS target population (not NCS participants).	60	1	1.33	80
Primary Data Collection	Pregnant Women/ Mothers of children ages 0–5. Mothers of children ages 0–5.	Members of NCS target population (not NCS participants).	600 600	2 1	1.08 1.08	1,300 650
Saliva Collection	Pregnant Women/ Mothers of children ages 0–5. Additional mothers of children ages 0–5. Children ages 0–5	Members of NCS target population (not NCS participants).	260 260 520	2 1 1	0.25 0.25 0.25	130 65 130
Total			1,780			2,460

Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Sarah L. Glavin, Deputy Director, Office of Science Policy, Analysis and Communication, National Institute of Child Health and Human Development, 31 Center Drive, Room 2A18, Bethesda, Maryland 20892, or call non-toll free number (301) 496–1877 or email your request, including your address to *glavins@mail.nih.gov.*

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: March 12, 2012.

Sarah L. Glavin,

Deputy Director, Office of Science Policy, Analysis and Communications, National Institute of Child Health and Human Development.

[FR Doc. 2012–6354 Filed 3–15–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, April 18, 2012, 1 p.m. to April 18, 2012, 5 p.m., National Institutes of Health, 6116 Executive Boulevard, 8055B, Rockville, MD 20852 which was published in the Federal Register on March 1, 2012, 77 FR 12600.

This notice is being amended to change the times of the meeting from 1 p.m.–5 p.m. to 12 p.m.–3 p.m. The meeting is closed to the public.

Dated: March 9, 2012.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–6352 Filed 3–15–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.